Lung Cancer
News
Atezolizumab combination regimen approved for advanced non-squamous NSCLC
The FDA approved checkpoint inhibitor atezolizumab for the treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor...
Feature
Trio of biosimilars have good showing
Community Translations
Paradigm-changing osimertinib approval in front-line for advanced NSCLC
Original Report
Symptom burdens related to chemotherapy-induced anemia in stage IV cancer
Conference Coverage
A novel tracer shows promise for detecting CD8 T-cells in advanced solid tumors
WASHINGTON – PET with 89Zr-IAB22M2C provides detailed information on CD8 T-cell biodistribution in patients with advanced solid tumors...
Conference Coverage
Lenvatinib/Pembrolizumab shows promise in previously treated metastatic NSCLC
WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and...
Conference Coverage
TMB measured by NGS may ID SCLC patients who will benefit from immunotherapy
WASHINGTON – Targeted next-generation sequencing may help identify SCLC patients likely to benefit from...
Conference Coverage
Immunotherapy-related toxicities may be more common than reported in trials
SAN DIEGO – Certain immune-related adverse events related to PD1/PD-L1 treatment of patients with non–small cell...
Conference Coverage
Early phase 2 data: Mocetinostat/durvalumab combo shows promise in mNSCLC
WASHINGTON, D.C. – Mocetinostat/durvalumab shows activity and manageable AEs in metastatic NSCLC after progression...
Conference Coverage
Capmatinib active against NSCLC with MET exon 14 mutations
MUNICH – Patients with MET exon 14–skipping mutations, but not MET gene amplification, had a high response rate to capmatinib.
News from the FDA/CDC
Cigarette smoking at lowest level ever
Prevalence dropped to 14% among adults in 2017, but control strategies need to “address the diversity of tobacco products.”